# A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

> **NCT01479595** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 65 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** QBX258
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01479595
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479595, "A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01479595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*